
Clinical Trial Reference Guide

Active and planned trials as of April 2025



www.CGOncology.com



Attacking Bladder Cancer for a Better Tomorrow™



Cretostimogene Monotherapy in Intermediate-Risk NMIBC

NCT06111235



Cretostimogene Monotherapy in BCG-Naïve, High-Risk NMIBC CIS or papillary only disease NCT06567743



Cretostimogene Monotherapy in BCG-Exposed, High-Risk NMIBC CIS or Papillary-only disease NCT06567743



Cretostimogene and gemcitabine combination therapy in BCG-exposed or BCG unresponsibe, High-Risk NMIBC CIS +/- Ta/T1 NCT06567743



Cretostimogene Monotherapy in BCG-Unresponsive, High-Risk NMIBC with CIS* NCT06443944



Cretostimogene Monotherapy in BCG-Unresponsive, High-Risk NMIBC Papillary-only disease NCT04452591

Important Inclusion/Exclusion Criteria**:

- Must be ≥18 years of age & ECOG 0-2 (0-3 for EAP)
- Must have adequate organ function
- Complete resection of papillary tumors prior to cretostimogene treatment initiation
- No muscle-invasive bladder carcinoma history
- No significant immunodeficiency, active infection, active hepatitis or recent major cardiovascular or surgical events
- For patients with a history of other malignancies, upper tract or prostatic urethral carcinoma, refer to specific protocol

Reference: 1. Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/ SUO guideline: 2024 amendment. J Urol. 2024;10.1097/JU.0000000000003846. 2. International Bladder Cancer Group Consensus Statement on ClinicalTrial Design for Patients with Bacillus Calmette-Guérin–exposed High-risk Non–muscle-invasive Bladder Cancer https://pubmed.ncbi.nlm.nih.gov/34955291/ 3. FDA Guidance Document: BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment. February 2018

- * This trial is for patients who are not eligible for our clinical trials and may not have options for alternative therapies.
- Please see clinical studies page on CGOncology.com for more information.

**see specific trial protocol for numerical & time-bound limits & additional criteria

CG Oncology is a trademark of CG Oncology Inc. © 2025 CG Oncology Inc. All rights reserved. US-UNBR-1086-v2

